Vivos Therapeutics dismisses Baker Tilly, names Haynie as new auditor
VVOS•Vivos Therapeutics dismissed Baker Tilly effective Sept. 29, 2026, and engaged Haynie & Company to audit the year ending Dec. 31, 2026. Audit opinions for 2024 and 2025 included going-concern warnings, but no adverse or disclaimer opinions.
1. Auditor change
Vivos Therapeutics dismissed Baker Tilly effective Sept. 29, 2026, and engaged Haynie & Company to audit the year ending Dec. 31, 2026. The company reported no disputes with Baker Tilly over accounting, disclosure or audit scope during 2024 and 2025 through the dismissal. Haynie held limited discussions in August 2026 about a proposed joint venture, but issued no accounting conclusion, and the transaction was not completed.
